Spruce biosciences and hmnc brain health announce strategic collaboration to develop treatment for major depressive disorder (mdd)

South san francisco, calif. & munich--(business wire)--spruce biosciences, inc. (nasdaq: sprb) (“spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, and hmnc brain health gmbh (“hmnc”), a global precision psychiatry biopharma company, announced today a strategic collaboration to develop spruce's investigational product candidate, tildacerfont, a second-generation.
SPRB Ratings Summary
SPRB Quant Ranking